Discover Viatris

Same Company, Different Operating System: Carlos’ Neurodiverse Journey

Access & Impact

Viatris Publishes 2024 Sustainability Report: Building Sustainable Access at Scale

Discover Viatris

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Discover Viatris

Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential